These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22505535)

  • 1. Editorial: Targeted therapy for HER-2: personalized medicine for her, too.
    Melichar B; Plebani M
    Clin Chem Lab Med; 2012 Jan; 50(1):1-4. PubMed ID: 22505535
    [No Abstract]   [Full Text] [Related]  

  • 2. HER-2-targeted therapy: lessons learned and future directions.
    Nahta R; Esteva FJ
    Clin Cancer Res; 2003 Nov; 9(14):5078-84. PubMed ID: 14613984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precise predictive and therapeutic strategy for breast cancer.
    Kyrochristos ID; Peristeri DV; Ziogas DE; Lykoudis EG; Roukos DH
    Future Oncol; 2018 Aug; 14(18):1777-1780. PubMed ID: 29846090
    [No Abstract]   [Full Text] [Related]  

  • 4. [Significance of HER2 testing in breast cancer].
    Ni YB; Yang WJ; Bu H; Zheng H
    Zhonghua Bing Li Xue Za Zhi; 2011 Feb; 40(2):76-8. PubMed ID: 21426800
    [No Abstract]   [Full Text] [Related]  

  • 5. [The requirements to clinicopathology about targeted therapy for breast cancer].
    Jiang ZF; Shen G
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):435-7. PubMed ID: 17845752
    [No Abstract]   [Full Text] [Related]  

  • 6. [Molecular phenotypes of breast cancer and their clinical application].
    Tang P; Wei B; Hicks DG; Skinner K; Bu H
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):13-7. PubMed ID: 19489219
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeted therapy for cancer: the HER-2/neu and Herceptin story.
    Ross JS; Gray GS
    Clin Leadersh Manag Rev; 2003; 17(6):333-40. PubMed ID: 14692077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation targeted agents in HER2-positive metastatic breast cancer.
    Perez EA
    Clin Adv Hematol Oncol; 2012 Jul; 10(7):465-7. PubMed ID: 22895288
    [No Abstract]   [Full Text] [Related]  

  • 9. Personalized medicine-molecular targeted cancer therapy.
    Osamura RY; Gown AM
    J Cell Mol Med; 2009; 13(11-12):4285. PubMed ID: 19691673
    [No Abstract]   [Full Text] [Related]  

  • 10. New research on the treatment of small HER2-positive breast cancers.
    Krop IE
    Clin Adv Hematol Oncol; 2014 Feb; 12(2):124-7. PubMed ID: 24892258
    [No Abstract]   [Full Text] [Related]  

  • 11. Where to with HER2?
    Sledge GW
    Clin Breast Cancer; 2010 Feb; 10(1):18. PubMed ID: 20133253
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?
    Chandarlapaty S; Modi S
    J Clin Oncol; 2011 Aug; 29(23):3111-3. PubMed ID: 21730267
    [No Abstract]   [Full Text] [Related]  

  • 13. In silico evaluation for the potential naturally available drugs for breast cancer.
    Vardhini SR
    J Recept Signal Transduct Res; 2014 Jun; 34(3):174-9. PubMed ID: 24329533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation binary targeted therapy for HER-2 positive breast cancers: assumptions, theoretical assessment and future directions.
    Mundy DW; Harb W; Jevremovic T
    Phys Med Biol; 2006 Mar; 51(6):1377-91. PubMed ID: 16510950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.
    Creedon H; Byron A; Main J; Hayward L; Klinowska T; Brunton VG
    Biochem Soc Trans; 2014 Aug; 42(4):822-30. PubMed ID: 25109964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.
    Hanna W; Kahn HJ; Trudeau M
    Mod Pathol; 1999 Aug; 12(8):827-34. PubMed ID: 10463486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.
    Meric-Bernstam F; Hung MC
    Clin Cancer Res; 2006 Nov; 12(21):6326-30. PubMed ID: 17085641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising therapeutic options in triple-negative breast cancer.
    Bilici A; Arslan C; Altundag K
    J BUON; 2012; 17(2):209-22. PubMed ID: 22740196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2 and fluorescent in situ hybridization to evaluate breast cancer.
    Tanvetyanon T
    JAMA; 2004 Jul; 292(3):328; author reply 328-9. PubMed ID: 15265845
    [No Abstract]   [Full Text] [Related]  

  • 20. Is precision medicine ready for use in breast cancer?
    Pusztai L
    Clin Adv Hematol Oncol; 2016 Dec; 14(12):964-966. PubMed ID: 28212357
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.